551 stories from 27 sources
The month in Medicine and Healthcare
Longest running story: 27 days
These infectious-disease crises made response capacity, surveillance, and public trust central healthcare concerns.
Click on a headline to see stories that shaped it.
Threads
8 threads
The Ebola outbreak grew from more than 3,000 deaths to more than 7,000 cases and nearly 3,400 deaths as it spread across Congolese provinces. By month’s end, officials were pairing vaccination and clinical research with surveillance across neighboring countries, but containment remained uneven.
Medical AI advanced from record access and supervised device testing toward prior authorization, clinical decisions, and broader adoption. High denial rates, data-access concerns, reimbursement costs, and fragmented oversight shifted the debate from capability to accountability.
Measles deaths and outbreaks intensified as routine immunization gaps left children vulnerable. Pennsylvania’s expanding toll and door-to-door outreach unfolded alongside disputes over federal vaccine messaging, making trust and communication part of the containment challenge.
The GLP-1 market expanded through Medicare as Lilly gained ground against Novo in oral and injectable drugs. Competition moved beyond efficacy toward manufacturing, pricing, delivery, treatment persistence, and the risks of stopping therapy.
Federal enforcement and court fights moved from a settlement involving one hospital to broader limits across dozens of US hospitals. Patients now face fewer providers, longer waits, and sharply different access depending on location.
Federal Medicaid cuts, work requirements, and ACA enrollment cancellations threatened coverage for millions. The month’s shift puts more pressure on states and makes administrative proof an increasingly direct barrier to care.
Gaza hospitals faced simultaneous shortages of oxygen, fuel, and engine oil, forcing rationing of generator power and reliance on scarce cylinders. The shortages threatened intensive care, surgery, neonatal treatment, and other services that require continuous support.
The administration expanded its drug-pricing agreements, but questions grew about which medicines they cover and whether savings reach patients. Scrutiny widened to contract transparency, Medicaid pricing, and claims about how broadly the strategy is being adopted.
Week’s Recap